Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients. Sarkozy C, Callanan MB, Thieblemont C, Oberic L, et al. Blood 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.

Read + Share

Amedeo Smart

Independent Medical Education

Sarkozy C, Callanan MB, Thieblemont C, Oberic L, et al. Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients. Blood 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
PMID: 38669626